Animal Models of Primary Aldosteronism

Abstract

Primary aldosteronism is considered the most prevalent form of secondary hypertension with pathophysiological and clinical features different from those of essential hypertension. Despite its high prevalence with the exception of the small subgroup of patients with familial hyperaldosteronism type I, the underlying genetic and molecular basis of this common disease is still largely unknown. In this context animal models can provide important insights in the physiology of aldosterone regulation that can serve as a starting point for investigation of mechanisms involved also in autonomous aldosterone secretion. Mouse models with defined genetic modification can further be utilized to prove functional relevance of these predefined candidate genes. Finally, animal models can be used to investigate cardiovascular and metabolic consequences of unopposed aldosterone secretion and potential restoration of these parameters through pharmacologic interventions. This review will provide a brief overview on animal models currently available for primary aldosteronism and describe in vivo screening strategies that are likely to aid in the elucidation of molecular and genetic mechanisms involved in autonomous aldosterone secretion.

Key words

primary aldosteronism - animal model - knock out mouse - transgenic mouse - aldosterone secretion - renin-angiotensin-aldosterone system

References

• 1 Williams GH, Rose LI, Dluhy RG, Dingman JF, Lauler DP. Aldosterone response to sodium restriction and ACTH stimulation in panhypopituitarism.  J Clin Endocrinol Metab. 1971;  32 27-35
• 2 Reincke M, Beuschlein F, Latronico AC, Arlt W, Chrousos GP, Allolio B. Expression of adrenocorticotrophic hormone receptor mRNA in human adrenocortical neoplasms: correlation with P450scc expression.  Clin Endocrinol (Oxf). 1997;  46 619-626
• 3 Himathongkam T, Dluhy RG, Williams GH. Potassim-aldosterone-renin interrelationships.  J Clin Endocrinol Metab. 1975;  41 153-159
• 4 Burnay MM, Python CP, Vallotton MB, Capponi AM, Rossier MF. Role of the capacitative calcium influx in the activation of steroidogenesis by angiotensin-II in adrenal glomerulosa cells.  Endocrinology. 1994;  135 751-758
• 5 Pezzi V, Clyne CD, Ando S, Mathis JM, Rainey WE. Ca(2+)-regulated expression of aldosterone synthase is mediated by calmodulin and calmodulin-dependent protein kinases.  Endocrinology. 1997;  138 835-838
• 6 Lu L, Suzuki T, Yoshikawa Y, Murakami O, Miki Y, Moriya T, Bassett MH, Rainey WE, Hayashi Y, Sasano H. Nur-related factor 1 and nerve growth factor-induced clone B in human adrenal cortex and its disorders.  J Clin Endocrinol Metab. 2004;  89 4113-4118
• 7 Bassett MH, Suzuki T, Sasano H, White PC, Rainey WE. The orphan nuclear receptors NURR1 and NGFIB regulate adrenal aldosterone production.  Mol Endocrinol. 2004;  18 279-290
• 8 Spyroglou A, Manolopoulou J, Wagner S, Bidlingmaier M, Reincke M, Beuschlein F. Short term regulation of aldosterone secretion after stimulation and suppression experiments in mice.  J Mol Endocrinol. 2009;  42 407-413
• 9 Brilla CG, Weber KT. Mineralocorticoid excess, dietary sodium, and myocardial fibrosis.  J Lab Clin Med. 1992;  120 893-901
• 10 Robert V, Silvestre JS, Charlemagne D, Sabri A, Trouve P, Wassef M, Swynghedauw B, Delcayre C. Biological determinants of aldosterone-induced cardiac fibrosis in rats.  Hypertension. 1995;  26 971-978
• 11 Young M, Fullerton M, Dilley R, Funder J. Mineralocorticoids, hypertension, and cardiac fibrosis.  J Clin Invest. 1994;  93 2578-2583
• 12 Brilla CG, Matsubara LS, Weber KT. Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension.  Am J Cardiol. 1993;  71 12A-16A
• 13 Young M, Head G, Funder J. Determinants of cardiac fibrosis in experimental hypermineralocorticoid states.  Am J Physiol. 1995;  269 E657-E662
• 14 Rainey WE, Saner K, Schimmer BP. Adrenocortical cell lines.  Mol Cell Endocrinol. 2004;  228 23-38
• 15 Yamazaki H, Abe Y, Katoh Y, Sawa N, Ohnishi Y, Tanaka Y, Sasano H, Oshika Y, Tokunaga T, Kijima H, Tamaoki N, Nakamura M, Ueyama Y. Establishment of an adrenocortical carcinoma xenograft with normotensive hyperaldosteronism in vivo.  Apmis. 1998;  106 1056-1060
• 16 Billet S, Bardin S, Verp S, Baudrie V, Michaud A, Conchon S, Muffat-Joly M, Escoubet B, Souil E, Hamard G, Bernstein KE, Gasc JM, Elghozi JL, Corvol P, Clauser E. Gain-of-function mutant of angiotensin II receptor, type 1A, causes hypertension and cardiovascular fibrosis in mice.  J Clin Invest. 2007;  117 1914-1925
• 17 Sausbier M, Arntz C, Bucurenciu I, Zhao H, Zhou XB, Sausbier U, Feil S, Kamm S, Essin K, Sailer CA, Abdullah U, Krippeit-Drews P, Feil R, Hofmann F, Knaus HG, Kenyon C, Shipston MJ, Storm JF, Neuhuber W, Korth M, Schubert R, Gollasch M, Ruth P. Elevated blood pressure linked to primary hyperaldosteronism and impaired vasodilation in BK channel-deficient mice.  Circulation. 2005;  112 60-68
• 18 Davies LA, Hu C, Guagliardo NA, Sen N, Chen X, Talley EM, Carey RM, Bayliss DA, Barrett PQ. TASK channel deletion in mice causes primary hyperaldosteronism.  Proc Natl Acad Sci U S A. 2008;  105 2203-2208
• 19 Czirjak G, Fischer T, Spat A, Lesage F, Enyedi P. TASK (TWIK-related acid-sensitive K+ channel) is expressed in glomerulosa cells of rat adrenal cortex and inhibited by angiotensin II.  Mol Endocrinol. 2000;  14 863-874
• 20 Heitzmann D, Derand R, Jungbauer S, Bandulik S, Sterner C, Schweda F, El Wakil A, Lalli E, Guy N, Mengual R, Reichold M, Tegtmeier I, Bendahhou S, Gomez-Sanchez CE, Aller MI, Wisden W, Weber A, Lesage F, Warth R, Barhanin J. Invalidation of TASK1 potassium channels disrupts adrenal gland zonation and mineralocorticoid homeostasis.  Embo J. 2008;  27 179-187
• 21 Bandulik S, Penton D, Barhanin J, Warth R. TASK1 and TASK3 potassium channels: determinants of aldosterone secretion and adrenocortical zonation  Horm Metab Res. in press 
• 22 Romero DG, Yanes LL, de Rodriguez AF, Plonczynski MW, Welsh BL, Reckelhoff JF, Gomez-Sanchez EP, Gomez-Sanchez CE. Disabled-2 is expressed in adrenal zona glomerulosa and is involved in aldosterone secretion.  Endocrinology. 2007;  148 2644-2652
• 23 Sheng Z, Sun W, Smith E, Cohen C, Xu XX. Restoration of positioning control following Disabled-2 expression in ovarian and breast tumor cells.  Oncogene. 2000;  19 4847-4854
• 24 Yang DH, Cai KQ, Roland IH, Smith ER, Xu XX. Disabled-2 is an epithelial surface positioning gene.  J Biol Chem. 2007;  282 13114-13122
• 25 Romero DG, Plonczynski MW, Welsh BL, Gomez-Sanchez CE, Zhou MY, Gomez-Sanchez EP. Gene expression profile in rat adrenal zona glomerulosa cells stimulated with aldosterone secretagogues.  Physiol Genomics. 2007;  32 117-127
• 26 Javadi S, Djajadiningrat-Laanen SC, Kooistra HS, van Dongen AM, Voorhout G, van Sluijs FJ, van den Ingh TS, Boer WH, Rijnberk A. Primary hyperaldosteronism, a mediator of progressive renal disease in cats.  Domest Anim Endocrinol. 2005;  28 85-104
• 27 Russell LB, Montgomery CS. Supermutagenicity of ethylnitrosourea in the mouse spot test: comparisons with methylnitrosourea and ethylnitrosourethane.  Mutat Res. 1982;  92 193-204
• 28 Popp RA, Bailiff EG, Skow LC, Johnson FM, Lewis SE. Analysis of a mouse alpha-globin gene mutation induced by ethylnitrosourea.  Genetics. 1983;  105 157-167
• 29 Grunwald DJ, Streisinger G. Induction of recessive lethal and specific locus mutations in the zebrafish with ethyl nitrosourea.  Genet Res. 1992;  59 103-116
• 30 Rinchik EM. Chemical mutagenesis and fine-structure functional analysis of the mouse genome.  Trends Genet. 1991;  7 15-21
• 31 Manolopoulou J, Bielohuby M, Caton SJ, Gomez-Sanchez CE, Renner-Mueller I, Wolf E, Lichtenauer UD, Beuschlein F, Hoeflich A, Bidlingmaier M. A highly sensitive immunofluorometric assay for the measurement of aldosterone in small sample volumes: validation in mouse serum.  J Endocrinol. 2008;  196 215-224

Correspondence